PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
PharmaEssentia (6446) - Net Assets
Latest net assets as of September 2025: NT$29.75 Billion TWD
Based on the latest financial reports, PharmaEssentia (6446) has net assets worth NT$29.75 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$34.45 Billion) and total liabilities (NT$4.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$29.75 Billion |
| % of Total Assets | 86.35% |
| Annual Growth Rate | 40.12% |
| 5-Year Change | 600.79% |
| 10-Year Change | 3883.53% |
| Growth Volatility | 336.13 |
PharmaEssentia - Net Assets Trend (2010–2024)
This chart illustrates how PharmaEssentia's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PharmaEssentia (2010–2024)
The table below shows the annual net assets of PharmaEssentia from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | NT$27.47 Billion | +14.70% |
| 2023-09-30 | NT$23.95 Billion | +97.25% |
| 2022-09-30 | NT$12.14 Billion | +185.65% |
| 2021-09-30 | NT$4.25 Billion | +8.44% |
| 2020-09-30 | NT$3.92 Billion | +73.82% |
| 2019-09-30 | NT$2.26 Billion | -8.77% |
| 2018-09-30 | NT$2.47 Billion | -28.50% |
| 2017-09-30 | NT$3.46 Billion | -19.04% |
| 2016-09-30 | NT$4.27 Billion | +519.29% |
| 2015-09-30 | NT$689.56 Million | -53.05% |
| 2014-09-30 | NT$1.47 Billion | -31.04% |
| 2013-09-30 | NT$2.13 Billion | +287.54% |
| 2012-09-30 | NT$549.52 Million | +1229.33% |
| 2011-09-30 | NT$41.34 Million | -83.07% |
| 2010-09-30 | NT$244.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaEssentia's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 410660200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$2.97 Billion | 10.83% |
| Common Stock | NT$3.42 Billion | 12.44% |
| Other Components | NT$21.08 Billion | 76.73% |
| Total Equity | NT$27.47 Billion | 100.00% |
PharmaEssentia Competitors by Market Cap
The table below lists competitors of PharmaEssentia ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spirax-Sarco Engineering plc
PINK:SPXSF
|
$5.84 Billion |
|
Sinomine Resource Exploration Co Ltd
SHE:002738
|
$5.85 Billion |
|
Eagle Materials Inc
NYSE:EXP
|
$5.85 Billion |
|
Direct Line Insurance Group PLC
PINK:DIISY
|
$5.85 Billion |
|
Compagnie Générale des Établissements Michelin Société en commandite par actions
PINK:MGDDF
|
$5.84 Billion |
|
Airports Of Thailand PCL
BK:AOT
|
$5.84 Billion |
|
Paramount Skydance Corporation Class B Common Stock
NASDAQ:PSKY
|
$5.84 Billion |
|
Turkish Airlines
IS:THYAO
|
$5.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaEssentia's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,948,150,000 to 27,468,844,000, a change of 3,520,694,000 (14.7%).
- Net income of 2,965,503,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 110,372,999.
- Other factors increased equity by 444,818,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$2.97 Billion | +10.8% |
| Other Comprehensive Income | NT$110.37 Million | +0.4% |
| Other Changes | NT$444.82 Million | +1.62% |
| Total Change | NT$- | 14.70% |
Book Value vs Market Value Analysis
This analysis compares PharmaEssentia's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 371.96x to 8.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-09-30 | NT$1.77 | NT$657.00 | x |
| 2011-09-30 | NT$0.30 | NT$657.00 | x |
| 2012-09-30 | NT$3.79 | NT$657.00 | x |
| 2013-09-30 | NT$10.66 | NT$657.00 | x |
| 2014-09-30 | NT$6.83 | NT$657.00 | x |
| 2015-09-30 | NT$3.19 | NT$657.00 | x |
| 2016-09-30 | NT$18.33 | NT$657.00 | x |
| 2017-09-30 | NT$13.92 | NT$657.00 | x |
| 2018-09-30 | NT$9.92 | NT$657.00 | x |
| 2019-09-30 | NT$9.16 | NT$657.00 | x |
| 2020-09-30 | NT$14.41 | NT$657.00 | x |
| 2021-09-30 | NT$14.73 | NT$657.00 | x |
| 2022-09-30 | NT$38.52 | NT$657.00 | x |
| 2023-09-30 | NT$66.96 | NT$657.00 | x |
| 2024-09-30 | NT$75.72 | NT$657.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaEssentia utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.80%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.46%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.13x
- Recent ROE (10.80%) is above the historical average (-70.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -68.50% | -314.98% | 0.17x | 1.27x | NT$-191.68 Million |
| 2011 | -492.66% | -1292.40% | 0.04x | 9.12x | NT$-207.79 Million |
| 2012 | -46.60% | -899.26% | 0.04x | 1.34x | NT$-311.01 Million |
| 2013 | -27.85% | -820.09% | 0.03x | 1.04x | NT$-806.11 Million |
| 2014 | -58.09% | -6387.44% | 0.01x | 1.13x | NT$-999.96 Million |
| 2015 | -123.73% | -7362.16% | 0.01x | 1.51x | NT$-922.16 Million |
| 2016 | -19.79% | -15437.93% | 0.00x | 1.05x | NT$-1.27 Billion |
| 2017 | -25.23% | -21618.54% | 0.00x | 1.06x | NT$-1.22 Billion |
| 2018 | -42.06% | -3963.10% | 0.01x | 1.13x | NT$-1.29 Billion |
| 2019 | -37.38% | -275.77% | 0.10x | 1.31x | NT$-1.07 Billion |
| 2020 | -49.70% | -349.59% | 0.10x | 1.41x | NT$-2.34 Billion |
| 2021 | -66.13% | -428.17% | 0.11x | 1.46x | NT$-3.24 Billion |
| 2022 | -11.32% | -47.70% | 0.19x | 1.26x | NT$-2.59 Billion |
| 2023 | -2.60% | -12.22% | 0.19x | 1.14x | NT$-3.02 Billion |
| 2024 | 10.80% | 30.46% | 0.31x | 1.13x | NT$218.62 Million |
Industry Comparison
This section compares PharmaEssentia's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaEssentia (6446) | NT$29.75 Billion | -68.50% | 0.16x | $5.84 Billion |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |